Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Pharma in Focus Jobs
Job satisfaction survey
Latest News
GSK in billion-pound restructure
GSK has revealed it is 'exploring' the potential for an initial public offering of HIV joint venture ViiV Healthcare and will be looking at restructuring its operations to save GBP 1 billion a year after disappointing quarterly results.
Sales growth but loss for API
Despite a $90.8m statutory loss for the year to August 31, API boss Stephen Roche says his company's retail result was very strong with the wholesaler's sales up by more than five per cent and an boost to underlying net profit.
GPs prove conservative on NOACs
Uptake of novel oral anticoagulants (NOACs) has been increasing slowly since their listing on the PBS - from 6.8 per cent in September 2013 to 18 per cent by July 2014 - but warfarin remains the anticoagulant of choice for GPs.
Tax fear can't stop Abbott and Mylan
Unlike AbbVie and Shire, Abbott and Alphapharm-owner Mylan are determined to go ahead with their $5.3 billion merger deal - with a few changes to protect tax gains.
$1bn-plus is Health's bet for Sovaldi
The government has a working estimate of more than $1bn over four years for the cost of hep C treatment Sovaldi after meeting a number of times with sponsor Gilead following rejection of its PBAC submission.
Code complaints near halved in 13-14
The industry has been well-behaved during the 2013-14 financial year, with only 10 new complaints made to Medicines Australia - a significant drop from the year before, when there were 18.
Patent fear keeping PBS prices up
Fear of the complexity, cost and unpredictability of patent busting actions, compounded by the Australia-US Free Trade Agreement is holding back generic medicines, a prominent pharma patent critic has alleged.
PDE5s backed for heart disease
New meta-analytical research published in the BMC Medicine journal has stated a case for sildenafil as a safe, daily treatment for heart disease.
We've saved PBS $650m says NPS
The NPS claims to have delivered $650m in 'validated' savings to the PBS in a submission to the new Senate Select Committee on Health. Pfizer, MA and the GMiA have also had their say.
Nov PBS listings in COPD, epilepsy
Two new drugs will be listed on the PBS from November 1 - Novartis's COPD treatment Ultibro Breezhaler and Eisai's epilepsy medicine Fycompa.
Humira wins new use, now for PBAC
Just in time for PBAC's November consideration of AbbVie's Humira, the company has won TGA approval for its use in treating Crohns disease in children.
AbbVie takes $1.6bn break with Shire
One of pharma's biggest M&A deals this year is finally over, with AbbVie and Shire announcing they have agreed to terminate, leaving AbbVie facing a US$1.6bn break fee.
Eylea ahead of Lucentis in DME
Bayer has received some good news about Eylea's efficacy in patients with diabetic macular oedema just as it heads to the PBAC to be considered for that indication in November.
Jobs go in Janssen restructure
A restructure at Janssen will mean the loss of 20 staff, the company has revealed as it tightens focus on what it is calling 'disease area strongholds'.
TGA processing time up slightly
TGA processing time for prescription medicine registrations increased by 11 working days from the first quarter of the year to the second quarter of the year, but remained 'well below' the statutory time frame.
Pharma investment needs more work
The Australian government is not doing too badly in encouraging multinational pharmas to invest here but certainly could improve, says Sanofi's regional head, partnering and external innovation.
Customers pick best pharmacy chain
A survey of pharmacy chain customers has shown Guardian Pharmacy leads but although placed third, Chemist Warehouse has double the market share of its nearest rivals.
Consumers cheer Code decision
The Consumers Health Forum is hailing the ACCC's imposition of onerous conditions on MA in return for authorisation of its new code of conduct as a victory for patients.
Industry attacked over trade pact
The pharma industry is being accused of using Trans-Pacific Partnership negotiations to feather its own nest after a major Wikileak revealed details of recent talks.
Sildenafil OTC in NZ, how about Aust?
With New Zealand having down-scheduled erectile dysfunction treatment, sildenafil, popularly known as Pfizer's Viagra, the push is on for reforms in Australia to improve consumer access.
AbbVie-Shire split not the last play
Even before the US$55 billion AbbVie-Shire deal is stone cold dead, speculation has started about other targets for the two newly single companies.
Novartis secures MS drug trademark
Novartis has won a trademark opposition case against French company Obvieline over the registration of 'Synectha' after alleging it was too close to its own multiple sclerosis brand Synacthen.
New therapies win NHMRC grants
Australia's $6 billion medical research sector has received a welcome boost with $539 million in new funding for researchers and research institutions, including for new drug trials.
'Innovation to zero' is next big thing
Zero side effects and zero lack of efficacy are the new targets for innovation as big data comes into its own for the pharma business, says Frost & Sullivan's Rhenu Buller.
EMA parts with FDA on testosterone
Conflicting regulatory messages are coming out of the EU and US in relation to testosterone treatment, with the European Medicines Agency finding evidence did not confirm an increase in cardiovascular risk with the therapy.
ACCC approves Code with conditions
In a blow to Medicines Australia, the ACCC has put its foot down on transparency reporting, saying that it will require changes to the new Code to include disclosures of all relevant transfers made to healthcare professionals.
AbbVie dumps bid for Shire
The US government's move to discourage tax inversion deals has scored its first big victim with AbbVie dumping its US$55 billion proposed takeover of Shire.
GSK denies Apotex $67m pain market
GSK has won an injunction against Apotex protecting, for the time being, its $67 million sustained release Panadol brands, including Panadol Osteo, from generic competition.
Roche racks up another tidy quarter
Roche has confirmed its full year outlook for 2014 after reporting overall sales up five per cent, with pharmaceuticals increasing sales by four per cent due to strong oncology growth.
Pay pharmacists like doctors: PSA
In a "dramatic shift" away from the current remuneration model for pharmacists, the Pharmaceutical Society of Australia wants them paid on a per consultation basis like doctors.
Survey finds over-use of pain meds
NPS MedicineWise is highlighting consumer survey showing that excess consumption of OTC pain killers - often bought in supermarkets - is not uncommon.
Guild rallies members as TVC starts
The Pharmacy Guild is calling on pharmacies to show a unified front by supporting its latest, multi-million dollar marketing campaign - due to start Sunday - saying it comes at a 'critical time for community pharmacy'.
Special Report
Aussie pharma market data: worth the price?
We asked market data users in Australian pharma for their opinions about the data they use and the providers who bring it to them and found some surprising, and some not so surprising, results.
Pipeline Monitor
Psoriasis market set for change
Novartis' first-in-class psoriasis drug secukinumab has been unanimously supported by FDA advisors while Celgene is celebrating encouraging results from its new Crohn's disease treatment.
Working Life
Social media profile, job friend or foe?
In a world of social media where people are continuously connected through their Facebook, LinkedIn, Instagram and Twitter accounts, how careful do pharma employees and job hunters have to be?
Approvals Action
First competitors for $56m Pfizer drug
Apotex has registered the first generic competition for Pfizer's antidepressant Pristiq while AbbVie has a new prefilled syringe for Lucrin Depot.
Open Forum
Generic myths: a pharmacist view
In the public mind, generic medicines continue to battle the idea that they are somehow inferior to original brands, but the pharmacy is not the same as the supermarket says Professor Andrew McLachlan.
FREE Content
Events & Conferences
Pharma in Focus Jobs
INC Research